Friday, December 11, 2009 | 8.00 PM - 10.00 PM Texas Ballroom, Salons A & B, 4th Floor
Grand Hyatt San Antonio
600 East Market Street, San Antonio, TX 78205
TARGET AUDIENCE
This educational activity is designed for medical oncologists, hematologists/oncologists, radiation oncologists, surgeons, and other healthcare providers worldwide whose scope of practice includes diagnosis, treatment, and management of patients with breast cancer.
SUPPORTERS
This
activity is supported by educational grants from Pfizer Inc.; Genomic Health
Inc.; Bayer HealthCare Corporation/Onyx Pharmaceuticals Inc.; and
sanofi-aventis.
FACULTY
Co-chairs:
Larry Norton, MD
Memorial Sloan-Kettering Cancer Center
New York, New York, United States
Martine Piccart-Gebhart, MD, PhD
Institute Jules Bordet
Brussels, Belgium
Faculty:
José Baselga, MD
Hospital Vall d'Hebron
Barcelona, Spain
Lisa Carey, MD
University of North Carolina
Chapel Hill, North Carolina, United States
Robert Coleman, MD
Weston Park Hospital
Sheffield, United Kingdom
Angelo Di Leo, MD, PhD
Hospital of Prato
Prato, Italy
Stephen Jones, MD
US Oncology Research
Dallas, Texas, United States
Terry Mamounas, MD
Northeastern Ohio Universities
Canton, Ohio, United States
Ian Smith, MD
Royal Marsden Hospital
London, United Kingdom
AGENDA
8.00 PM
Introduction Larry Norton, MD
Martine Piccart-Gebhart, MD, PhD
8.10 PM
Theme #1: Triple-negative breast cancer: Improving outcomes
Variation 1: How chemosensitive is triple-negative (basal-like) breast cancer? Ian Smith, MD
Variation 2: Incorporating targeted agents: When and in what sequence? Lisa Carey, MD
Questions for improvisations
8.40 PM
Theme #2: Adjuvant systemic therapy for postmenopausal endocrine-responsive breast cancer: Multiple variations on a central theme
Variation 1: Risk assessment and the role of gene expression profiles in treatment planning Terry Mamounas, MD
Variation 2: Systemic adjuvant therapy: What's the best approach? Stephen Jones, MD
Variation 3: Addressing concerns regarding bone health Robert Coleman, MD
Questions for improvisations
9.25 PM
Theme #3: Metastatic HER2-amplified breast cancer: Therapeutic options
Variation 1: Disease progression following adjuvant trastuzumab: What's next? Angelo Di Leo, MD, PhD
Variation 2: What if progression occurs during trastuzumab? José Baselga, MD
Questions for improvisations
9.55 PM
Conclusion Larry Norton, MD
Martine Piccart-Gebhart, MD, PhD
LEARNING OBJECTIVES
The information presented at this education activity should improve your ability to:
Consider the role of risk estimation when developing treatment plans for patients with breast cancer
Select appropriate adjuvant therapy for patients with breast cancer who are endocrine responsive and postmenopausal
Integrate best evidence and clinical data when treating patients with triple-negative metastatic breast cancer
Utilize optimal strategies for the management of patients with HER2-positive disease, including but not limited to trastuzumab-resistant disease
